Improving Prediction of Cardiovascular Complications of Cancer Therapy: What Does the Future hold?

References

• Seidman A , HudisC, PierriMKet al. Cardiac dysfunction in the trastuzumab clinical trials experience . J. Clin. Oncol.20 ( 5 ), 1215 – 1221 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Cote GM , SawyerDB, ChabnerBA . ERBB2 inhibition and heart failure . N. Engl. J. Med.367 ( 22 ), 2150 – 2153 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sparano JA . Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials . Semin. Oncol.28 ( 1 Suppl. 3 ), 20 – 27 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Romond EH , JeongJH, RastogiPet al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer . J. Clin. Oncol.30 ( 31 ), 3792 – 3799 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kumler I , TuxenMK, NielsenDL . A systematic review of dual targeting in HER2-positive breast cancer . Cancer Treat. Rev.40 ( 2 ), 259 – 270 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ewer MS , Von HoffDD, BenjaminRS . A historical perspective of anthracycline cardiotoxicity . Heart Fail. Clin.7 ( 3 ), 363 – 372 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Vejpongsa P , YehET . Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities . J. Am. Coll. Cardiol.64 ( 9 ), 938 – 945 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhang S , LiuX, Bawa-KhalfeTet al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity . Nat. Med.18 ( 11 ), 1639 – 1642 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vejpongsa P , YehET . Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity . Clin Pharmacol Ther.95 ( 1 ), 45 – 52 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ky B , VejpongsaP, YehET, ForceT, MoslehiJJ . Emerging paradigms in cardiomyopathies associated with cancer therapies . Circ Res.113 ( 6 ), 754 – 764 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Crone SA , ZhaoYY, FanLet al. ErbB2 is essential in the prevention of dilated cardiomyopathy . Nat. Med.8 ( 5 ), 459 – 465 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Ky B , KimmelSE, SafaRNet al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure . Circulation120 ( 4 ), 310 – 317 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sawyer DB , ZuppingerC, MillerTA, EppenbergerHM, SuterTM . Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity . Circulation105 ( 13 ), 1551 – 1554 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Chu TF , RupnickMA, KerkelaRet al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib . Lancet370 ( 9604 ), 2011 – 2019 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Moslehi J , MinamishimaYA, ShiJet al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy . Circulation122 ( 10 ), 1004 – 1016 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Barac A . Yet another player in the cardio-oncology conundrum?: deciphering the role of FLT3 . J. Am. Coll. Cardiol.63 ( 10 ), 1020 – 1021 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shelburne N , AdhikariB, BrellJet al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities . J. Natl Cancer Inst.106 ( 9 ), dju232 ( 2014 ).
   PubMedGoogle Scholar
• Cardinale D , SandriMT, ColomboAet al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy . Circulation109 ( 22 ), 2749 – 2754 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , ColomboA, TorrisiRet al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation . J. Clin. Oncol.28 ( 25 ), 3910 – 3916 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , RifaiN, SallanSEet al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury . Circulation96 ( 8 ), 2641 – 2648 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , MillerTL, ScullyREet al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes . J. Clin. Oncol.30 ( 10 ), 1042 – 1049 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ky B , FrenchB, RuparelKet al. The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure . J. Am. Coll. Cardiol.58 ( 4 ), 386 – 394 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ky B , PuttM, SawayaHet al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab . J. Am. Coll. Cardiol.63 ( 8 ), 809 – 816 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Motiwala SR , SzymonifkaJ, BelcherAet al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling . J. Cardiovasc. Transl. Res.7 ( 2 ), 250 – 261 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sawaya H , SebagIA, PlanaJCet al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients . Am. J. Cardiol.107 ( 9 ), 1375 – 1380 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sawaya H , SebagIA, PlanaJCet al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab . Circ. Cardiovasc. Imaging5 ( 5 ), 596 – 603 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P , PoulinF, LimKD, PlanaJC, WooA, MarwickTH . Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review . J. Am. Coll. Cardiol.63 ( 25 Pt A ), 2751 – 2768 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Toro-Salazar OH , GillanE, O’LoughlinMTet al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy . Circ. Cardiovasc. Imaging6 ( 6 ), 873 – 880 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Jordan JH , D’AgostinoRBJ, HamiltonCAet al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using t1-weighted and t2-weighted cardiovascular magnetic resonance . Circ. Cardiovasc. Imaging7 ( 6 ), 872 – 879 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lightfoot JC , D’AgostinoRBJ, HamiltonCAet al. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model . Circ. Cardiovasc. Imaging3 ( 5 ), 550 – 558 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ling Y , PongT, VassiliouCC, HuangPL, CimaMJ . Implantable magnetic relaxation sensors measure cumulative exposure to cardiac biomarkers . Nat. Biotechnol.29 ( 3 ), 273 – 277 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Tham EB , HaykowskyMJ, ChowKet al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling . J. Cardiovasc. Magn. Reson.15, 48 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bowles EJ , WellmanR, FeigelsonHSet al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study . J. Natl Cancer Inst.104 ( 17 ), 1293 – 1305 ( 2012 ).
   PubMedGoogle Scholar
• Darby SC , EwertzM, McGalePet al. Risk of ischemic heart disease in women after radiotherapy for breast cancer . N. Engl. J. Med.368 ( 11 ), 987 – 998 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tsai HT , IsaacsC, FuAZet al. Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study . Breast Cancer Res. Treat.144 ( 1 ), 163 – 170 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ezaz G , LongJB, GrossCP, ChenJ . Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer . J. Am. Heart Assoc.3 ( 1 ), e000472 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Strimbu K , TavelJA . What are biomarkers?Curr. Opin. HIV AIDS.5 ( 6 ), 463 – 466 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Barac A , MurtaghG, CarverJRet al. Council Clinical Perspective: cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level . J. Am. Coll. Cardiol.65 ( 25 ), 2739 – 2746 ( 2015 ).
   PubMed Web of Science ®Google Scholar